Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 10/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201646 | 0.80 | HRH1 (0.34) | TLR9TLR8TLR7HTR6HRH1 | |
| SCHEMBL16201641 | 0.78 | FEN1 (0.36) | TLR9TLR8TLR7DYRK1A | |
| SCHEMBL16201631 | 0.77 | MTNR1A (0.45) | HTR6HRH1 | |
| SCHEMBL16201633 | 0.76 | TLR8 (0.38) | TLR9TLR8TLR7 | |
| SCHEMBL16201655 | 0.74 | PDE4A (0.41) | TLR9TLR8TLR7 | |
| SCHEMBL16201637 | 0.72 | FEN1 (0.35) | TLR9TLR8TLR7 | |
| SCHEMBL16201632 | 0.69 | FEN1 (0.35) | TLR9TLR8TLR7 | |
| SCHEMBL16201636 | 0.69 | PDE4A (0.36) | TLR9TLR8TLR7 | |
| SCHEMBL29302055 | 0.68 | FEN1 (0.44) | TLR9TLR8TLR7DYRK1A | |
| SCHEMBL14995760 | 0.67 | HDAC6 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345905-B2 | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | BETA PHARMA CANADA INC. (CA) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | HDAC6, HDAC1, HDAC7 | TLR9 1837/4885TLR8 2001/4885TLR7 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.